Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Existing Diseases Orphaned: Proposed Rule May Split Large Classes Into Subsets

Executive Summary

FDA will amend its orphan drug regulations to specify the requirements for a disease subset to qualify as a rare disease for the purpose of orphan designations

You may also be interested in...



Orphan, But Not Rare: Pipeline Is Full And Approvals Are Up

If current trends persist, in 2006 FDA could surpass the number of orphan status designations granted in the past two years

FDA To Provide Updates On Critical Path Opportunities List Projects

FDA will highlight the agency's involvement in Critical Path projects in the coming months, Deputy Commissioner for Operations Janet Woodcock said March 16

Orphan Drug Act

"Based on our surveys of patient groups and sponsors and our review of the FDA database on designations and approvals, we conclude that no regulatory or legislative changes are needed at this time," General Accounting Office report on the Orphan Drug Act concludes

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel